Led by:
Dr. Melchor Álvarez de Mon Soto.

ProA Capital had the chance of supporting a great initiative related to effective treatments and medication.

As it has been observed, each patient’s immune system reacts to the coronavirus in many different ways, being the most severe cases those in which the own immune system generates a fatal out-of-proportion overreaction.

Access the presentation


Research Project

Biomedical Characterization of patients for therapeutic individualization

The Project aims to analyze evolutionarily the cellular components of the immune system in blood for a sample of over 300 infected patients. We will analyze the intensity and the alterations of the main cellular components of the immune system. With the result of this study, we intend to characterize and typify patients in order to achieve therapeutic individualization from the beginning of the infection. We believe that defining biomarkers will allow to anticipate a more appropriate individualized treatment, including immunomodulators, for each patient at the beginning of their infection.

It has been observed that is it essential to start treatment before a perfect storm of hyperinflammation, caused by uncontrolled release of cytokines, lymphocytes and macrophages, unfolds in the patient. In short, it is key to know accurately which treatment and medication a future patient of COVID-19 will require during each stage of the disease. Until an effective vaccine is released, the objectives of this Project are characterizing patients and individualizing their therapies.

The Practical Research Project will be carried out by a multidisciplinary team led by Professor Melchor Álvarez de Mon. His CV is impressive:

  • Professor of Medicine and Immune System Diseases
  • Head of Service at Universidad de Alcalá de Henares (UAH)
  • Head of Service of Immune System Diseases and Oncology at Hospital Universitario Príncipe de Asturias
  • Corresponding Academic from the Real Academia Nacional de Medicina and first President of the Comisión Científica e Investigación of Colegio de Médicos de Madrid
  • Founding director of the Laboratory of Immune System Diseases of the UAH
  • Visiting lecturer at Stanford, Philadelphia, Rochester, Texas, California, Emory Universities, Pfizer MIT and Mayo Clinic
  • Medal of Service in Healthcare awarded by the Medical Community
  • Coordinator of the Joint Unit with Centro Nacional de Biotecnología (CNB)

The project has a budget of 450,000 euros for Phase I, channeled through the sponsorship activities of the Universidad de Alcalá (UAH).

The ProA Capital Team along with some of our invested companies committed a significant amount of the funds. In addition, we will collaborate in the analysis of big data and we will cross it with other data bases.

Detailed description of the project
COVID-19 Research ProA Capital Starlite